Functionalized aminobenzoboroxoles

1. A compound having the structure of formula (I):

or a pharmaceutically acceptable salt thereof, wherein

R 1 is hydrogen, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, optionally substituted C 6-10 aryl, optionally substituted 5-10 membered heteroaryl, optionally substituted C 3-10 carbocyclyl, or optionally substituted 3-10 membered heterocyclyl;

each of R 2 , R 3 , R 4 and R 5 is independently hydrogen, halogen, hydroxy, optionally substituted C 1-6 alkyl, optionally substituted C 2-6 alkenyl, optionally substituted C 2-6 alkynyl, optionally substituted C 1-6 alkoxy, optionally substituted C 1-6 alkylthio, optionally substituted C 2-8 alkoxyalkyl, C 1-6 haloalkyl, C 1-6 hydroxyalkyl, —CN, NO 2 , O-carboxy, C-carboxy, O-amido, C-amido, sulfinyl, sulfonyl, S-sulfonamido, N-sulfonamido, amino, optionally substituted aminoalkyl, optionally substituted C 6-10 aryl, optionally substituted C 7-14 aralkyl, optionally substituted 5-10 membered heteroaryl, optionally substituted C 3-10 carbocyclyl, or optionally substituted 3-10 membered heterocyclyl;

R 6 is hydrogen, optionally substituted C 1-6 alkyl, —N(═O), or —C(═O)NR 8 R 9 ;

R 7 is —(CH 2 ) m -(5-10 membered heteroaryl), —(CH 2 ) m —(C 3-10 carbocyclyl), or —(CH 2 ) m -(3-10 membered heterocyclyl), each optionally substituted with one or more R 10 , or —(CH 2 ) m —(C 6-10 aryl) substituted with one or more R 10 ;

each R 8 and R 9 is independently hydrogen, optionally substituted C 1-6 alkyl, C 1-6 haloalkyl, optionally substituted C 2-6 alkenyl, optionally substituted C 2-6 alkynyl, optionally substituted C 2-8 alkoxyalkyl, optionally substituted C 3-10 carbocyclyl, optionally substituted C 6-10 aryl, optionally substituted C 7-14 aralkyl, optionally substituted 5-10 membered heteroaryl, or optionally substituted 3-10 membered heterocyclyl;

R 10 is hydroxy, halogen, optionally substituted C 2-6 alkenyl, optionally substituted C 2-6 alkynyl, optionally substituted C 1-6 alkoxy optionally substituted C 1-6 alkylthio, optionally substituted C 2-8 alkoxyalkyl, C 1-6 hydroxyalkyl, optionally substituted C 3-10 carbocyclyl, optionally substituted C 6-10 aryl, optionally substituted C 7-14 aralkyl, optionally substituted 5-10 membered heteroaryl, or optionally substituted 3-10 membered heterocyclyl, —CN, —NO 2 , O-carboxy, C-carboxy, O-amido, C-amido, sulfinyl, sulfonyl, S-sulfonamido, N-sulfonamido, amino, or optionally substituted aminoalkyl;

m is an integer selected from 1 to 6; and

n is 1.

2. The compound of claim 1 , wherein the compound of formula (I) is also represented by formula (Ia):

or a pharmaceutically acceptable salt thereof.

3. The compound of claim 1 , wherein R 1 is hydrogen or C 1-6 alkyl.

4. The compound of claim 1 , wherein R 2 is hydrogen.

5. The compound of claim 1 , wherein at least one of R 3 , R 4 or R 5 is hydrogen.

6. The compound of claim 1 , wherein R 6 is hydrogen, —N(═O), or —C(═O)NR 8 R 9 .

7. The compound of claim 6 , wherein R 8 is hydrogen, and wherein R 9 is optionally substituted C 6-10 aryl, optionally substituted C 1-6 alkyl or optionally substituted C 3-10 carbocyclyl.

8. The compound of claim 7 , wherein R 9 is phenyl, C 1-6 haloalkyl, or optionally substituted cyclohexyl.

9. The compound of claim 1 , wherein R 7 is —(CH 2 ) m —(C 6-10 aryl) substituted with one or more R 10 .

10. The compound of claim 9 , wherein m is 1 and R 7 is —CH 2 -phenyl substituted with one or more R 10 .

11. The compound of claim 10 , wherein R 7 is substituted with one or more R 10 selected from the group consisting of halogen, hydroxy, —C(═O)OH, C-amido, —CN, C 1-6 alkoxy, —N(C 1-6 alkyl) 2 , and piperidinyl.

12. The compound of claim 1 , wherein R 7 is —(CH 2 ) m -(3-10 membered heterocyclyl) optionally substituted with one or more R 10 .

13. The compound of claim 12 , wherein m is 1 and R 7 is —CH 2 -9 membered heterocyclyl optionally substituted with one or more R 10 .

14. The compound of claim 1 , wherein R 7 is —(CH 2 ) m -(5-10 membered heteroaryl) optionally substituted with one or more R 10 .

15. The compound of claim 14 , wherein m is 1 and R 7 is —CH 2 -10 membered heteroaryl optionally substituted with one or more halogen.

16. The compound of claim 15 , wherein R 7 is —CH 2 -quinolinyl substituted with one or more halogen.

17. The compound of claim 1 , selected from the group consisting of

and pharmaceutically acceptable salts thereof.

18. A pharmaceutical composition comprising an effective amount of a compound of claim 1 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, diluent, excipient or combination thereof.

19. A method of therapeutically treating breast cancer or prostate cancer, comprising administering a therapeutically effective amount of a compound of claim 1 or a pharmaceutically acceptable salt thereof to a subject in need thereof.